Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Segulah Medical Acceleration (SMA) is a Stockholm-based venture capital firm managing approximately SEK 1.3 billion (around EUR 120 million). The firm focuses on bridging the gap between research and commercialization in the medical technology sector. SMA supports technology-driven companies, particularly in the Nordic region, with a portfolio of 9 companies.
SMA invests in medical devices, diagnostics, life science tools, and health technology, primarily at the pre-seed, seed, seed+, and growth equity stages. The firm targets products that are at the finished product stage and have global scaling potential, emphasizing early commercialization in Europe.
Notable companies in SMA's portfolio include Senzime, Collective Minds Radiology, Navinci Diagnostics, Protembis, Allurion Technologies, SAGA Dx, Signifier Medical Technologies, Quanta Dialysis Technologies, and CytaCoat.
Email your pitch deck to dealflow@segulahmedical.com for consideration.
As of January 16, 2026: SMA's portfolio company, Saga Diagnostics, launched Pathlight™ MRD for colorectal cancer, showcasing the firm's commitment to supporting advancements in medical technology.
SMA typically participates in rounds but often collaborates with other investors to lead investments in promising medical technologies.
The firm is open to follow-on investments, particularly for portfolio companies demonstrating strong growth and scaling potential.
SMA manages approximately SEK 1.3 billion, which is around EUR 120 million, dedicated to investing in the medtech sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.